ARCA Biopharma announces completion of GENETIC-AF Clinical Trial
ARCA biopharma announced the completion of patient follow-up for GENETIC-AF, a Phase 2B, double-blind, superiority clinical trial evaluating Gencaro as a potential genetically-targeted treatment for atrial fibrillation, or AF. All patients completed their last study visits and were transitioned off study drug by the end of December 2017. ARCA expects to report top-line Phase 2B data in March 2018. "Completion of patient treatment in GENETIC-AF represents a key clinical milestone for ARCA and we look forward to reporting top-line data for the trial, which we estimate should include approximately 50% more events than were available at the previously conducted interim analysis," commented Dr. Michael Bristow, ARCA's President and CEO. "I would like to thank our clinical investigators as well as the patients and their families for their participation. We will continue working diligently to advance Gencaro's pharmacogenetic clinical and regulatory development."